Genome Wide Association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel desease

Inflammatory Bowel Diseases

Volumn 16, Issue 8, 2010, Pages 1357-1366

  Dubinsky, Marla C ^a   Mei, Ling ^a   Friedman, Madison ^a   Dhere, Tanvi ^b   Haritunians, Talin ^a   Hakonarson, Hakon ^c   Kim, Cecilia ^c   Glessner, Joseph ^c   Targan, Stephan R ^a   McGovern, Dermot P ^a   Taylor, Kent D ^a   Rotter, Jerome I ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Anti TNF ; Genotype; IBD; Pharmacogenetics; Phenotype; Therapy

Indexed keywords

INFLIXIMAB;

ARTICLE; CHI SQUARE TEST; CHILD; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL AGENTS; GENETIC LOCI; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77953787089     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21174     Document Type: Article

References (31)

1. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
2. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.
3. Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1541-1549.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
6. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
8. Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther. 2004;20:303-310. (Pubitemid 39062133)
9. Mascheretti S, Hampe J, Kuhbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics. 2002;2:127-136. (Pubitemid 34982216)
10. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824. (Pubitemid 34836819)
11. Taylor KD, Plevy SE, Yang H, et al. LTa 1-1-1-1 haplotype is associated with negative response in Crohn's disease ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
12. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximabin Crohn's disease. Gastroenterology. 2002;123:106-111.
13. Urcelay E, Mendoza JL, Martinez A, et al. IBD 5 (5q31) TT is associated with negative response in Crohn's disease. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J Gastroenterol. 2005;11:1187-1192.
14. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
15. Franke A, Balschun T, Karlsen TH, et al. the IBSEN study group. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:710-712.
16. Fisher SA, Tremelling M, Anderson CA, et al. Wellcome Trust Case Control Consortium. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet. 2008;40:710-712.
17. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41:216-220.
18. Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40:1211-1215.
19. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. (Pubitemid 46806219)
20. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810-1819.
21. Anderson CA, Massey DC, Barrett JC, et al. Wellcome Trust Case Control Consortium. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology. 2009;136:523-529.
22. Dubinsky MC, Kugathasan S, Mei L, et al. for the Western Regional Pediatric IBD Research Alliance, Pediatric IBD Collaborative Research Group and the Wisconsin Pediatric IBD Alliance. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
23. Gunderson KL, Steemers FJ, Lee G, et al. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet. 2005;37:549-554. (Pubitemid 40617286)
24. Harvey RF, Bradshaw JM.A simple Index of Crohn's disease activity. Lancet. 1980;1:514.
25. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904-909. (Pubitemid 44141658)
26. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575. (Pubitemid 47330214)
27. Stokes, ME, Davis CS, Koch, GG. Categorical data analysis using the SAS system, 2nd ed. Cary, NC: SAS Press; 2000.
28. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research, 4th ed. Malden, MA: Wiley-Blackwell; 2002.
29. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet. 2005;14:3499-3506.
30. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359:789-9931.
31. Burgner D, Davila S, Breunis WB, et al, International Kawasaki Disease Genetics Consortium. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet. 2009;5:e1000319.